Frank is Founder, CEO and CIO of Ally Bridge Group, a global healthcare-focused, multi-strategy investment group with a portfolio of healthcare investments in China, the US and Europe. In 2015, Ally Bridge Group, initiated, led and completed the landmark USD3.3 billion take-private of Wuxi Pharmatech, a leading global life science service company, in close collaboration with the company’s founder/chairman/CEO.
Frank personally is always very actively involved in investing companies all the way from deal origination to exit, and has expertise in cementing strategic transactions between emerging players and industry leaders, between global companies and Chinese companies, and helping global companies to access the China market while assisting Chinese companies to acquire novel technologies overseas.
Frank’s successful finance career has spanned risk management, investment banking and multi-strategy investing from private equity and venture capital to hedge fund investing.
Previously, Mr. Yu was Managing Director and Head of China Investments at Och-Ziff Capital Management (OZ), a leading global hedge fund, where he made some of OZ’s largest and successful investments. Prior to Och-Ziff, Mr. Yu was a Managing Director at Goldman Sachs in Hong Kong, where he headed several business units and played instrumental roles in some of the most important restructuring, IPO and M&A transactions of leading Chinese companies. Mr. Yu also advised leading global institutions on their China and Asia strategies and transactions. Before Goldman Sachs, Mr. Yu worked at Moody’s in New York, and then Credit Suisse in London and Hong Kong.